|
|
Examination of the genes DNM2, GARS, MORC2, TRPV4 and SOD1 among Czech patients with hereditary neuropathy axonal type
Neupauerová, Jana ; Laššuthová, Petra (advisor) ; Vlčková, Eva (referee) ; Vasovčák, Peter (referee)
Examination of the genes DNM2, GARS, MORC2, TRPV4 and SOD1 among Czech patients with hereditary neuropathy axonal type For my PhD thesis I chose to work with patients with axonal form of CMT, because at that time axonal forms were less likely to be clarified by classical methods of molecular genetics. For further examination in patients with unclear cause of the axonal CMT, the genes DNM2, GARS and TRPV4 were selected. The aim was to determine the significance of pathogenic mutations in these genes as the cause of CMT2 in Czech patients. In the course, we identified causal variants in the genes MORC2 and SOD1 with WES. Therefore, we have tested additional CMT2 patients for the presence of these variants. Using Sanger sequencing, I examined a representative set of patients for the DNM2 (37), GARS (10) and TRPV4 (24) genes without finding a causal mutation, then we investigated genes SOD1 (43 patients) and MORC2 (161 patients). The cohort (50 patients) was also subjected to MLPA analysis using a P406-A1 CMT2 duplication and deletion detection kit for genes RAB7A, GARS, HSPB1, HSBP8 and SPTLC1 (kit P406-A1 CMT2). At that time, massively parallel sequencing (MPS) was becoming important. We compared the cost of classical sequencing versus MPS, and accordingly, we decided that the genes DNM2, GARS, MORC2, TRPV4...
|
|
|
Examination of the genes DNM2, GARS, MORC2, TRPV4 and SOD1 among Czech patients with hereditary neuropathy axonal type
Neupauerová, Jana ; Laššuthová, Petra (advisor) ; Vlčková, Eva (referee) ; Vasovčák, Peter (referee)
Examination of the genes DNM2, GARS, MORC2, TRPV4 and SOD1 among Czech patients with hereditary neuropathy axonal type For my PhD thesis I chose to work with patients with axonal form of CMT, because at that time axonal forms were less likely to be clarified by classical methods of molecular genetics. For further examination in patients with unclear cause of the axonal CMT, the genes DNM2, GARS and TRPV4 were selected. The aim was to determine the significance of pathogenic mutations in these genes as the cause of CMT2 in Czech patients. In the course, we identified causal variants in the genes MORC2 and SOD1 with WES. Therefore, we have tested additional CMT2 patients for the presence of these variants. Using Sanger sequencing, I examined a representative set of patients for the DNM2 (37), GARS (10) and TRPV4 (24) genes without finding a causal mutation, then we investigated genes SOD1 (43 patients) and MORC2 (161 patients). The cohort (50 patients) was also subjected to MLPA analysis using a P406-A1 CMT2 duplication and deletion detection kit for genes RAB7A, GARS, HSPB1, HSBP8 and SPTLC1 (kit P406-A1 CMT2). At that time, massively parallel sequencing (MPS) was becoming important. We compared the cost of classical sequencing versus MPS, and accordingly, we decided that the genes DNM2, GARS, MORC2, TRPV4...
|
|
| |
|
|
New antithrombotics and laboratory tests for monitoring their effect
Hadravová, Jiřina ; Bártů, Iva (advisor) ; Neupauerová, Jana (referee)
This bachelor work follows up the comparison of new antithrombotics with the existing commonly used drugs. The theoretical part describes the individual drugs, their characteristics, indications, advantages and disadvantages. The work presents a comparison of the need for routine laboratory monitoring of individual drugs. The practical part of this work describes methods for the determination of the existing and new drugs and compare them. The work contains the results of measurements of new antithrombotics by the individual methods of determination. I compared the measured results of the commonly used methods with methods designed directly for the determination of new antithrombotics and I evaluate which routine methods can be used to approximate assessment of new preparations. The samples from patients treated with anticoagulant therapy and healthy persons provided the Department of Clinical Hematology, University Hospital Motol in Prague. Powered by TCPDF (www.tcpdf.org)
|
|
| |
guest ::
